A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor
1996

Study of ZD1694 in Advanced Breast Cancer

Sample size: 46 publication Evidence: moderate

Author Information

Author(s): I Smith, A Jones, M Spielmann, M Namer, MD Green, J Bonneterre, HE Wander, T Hatschek, N Wilking, J Zalcberg, J Spiers, L Seymour

Primary Institution: Royal Marsden Hospital

Hypothesis

Does ZD1694 provide effective treatment for advanced breast cancer?

Conclusion

ZD1694 shows useful activity in hormone-refractory advanced breast cancer with an overall response rate of 26%.

Supporting Evidence

  • 26% of evaluable patients achieved a complete or partial response.
  • 44% response rate was observed in patients with liver metastases.
  • 85% of patients received their scheduled dose without significant delay.

Takeaway

This study tested a new drug called ZD1694 on women with advanced breast cancer, and it helped some of them feel better.

Methodology

Patients received ZD1694 at a dose of 3.0 mg m-2 as a short infusion every 3 weeks, and their responses were evaluated.

Limitations

The study had a small sample size and was limited to patients with specific prior treatments.

Participant Demographics

The mean age of participants was 58 years, with 98% being Caucasian.

Statistical Information

Confidence Interval

95% CI 14-42%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication